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The purpose of this decision-making tool, is to help research and development (R&D) 
project planners mitigate the risk of project setbacks or failures, as a result of not 
being able to access genetic resources and related research inputs, to use them as 
needed for project purposes, or to disseminate research products derived from their 
use. It is intended primarily for planners of projects that rely on accessing, pooling 
and sharing a diverse portfolio of genetic resources from multiple sources in different 
countries and continents; projects for which the risks are substantially increased, in 
proportion to the diversity and number of sources of genetic resources they rely upon.
This tool responds to the fact that – as a result of an 
increasingly complex mix of social, political, technological and 
legal developments – there is a very real risk that potential 
providers of genetic resources (including research partners) 
will be not be willing or able to make them available for use in 
research projects.
Understandably, many scientists and research managers are not fully aware of these 
risks, and are therefore surprised when they start to encounter challenges after 
their projects are funded and initiated: challenges that can require them to alter or 
terminate planned activities, to find and work with alternative genetic resources and 
partners, and to suffer delays and added costs.
This tool is designed to raise scientists’ awareness of the risks 
involved, so they can take them into consideration in the 
earliest stages of project planning.
 
It sets out questions that scientists need to ask themselves as part of the process of 
assessing the risks to their own plans under development, and lists optional strategies 
and ‘go/no go’ decision-making points to help with mitigating those risks in the 
project planning stages.
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Influence of combined social, political, technological and legal 
developments
The combined social, political, technological and legal developments that have 
contributed to the current state of uncertainty and unpredictability concerning the 
availability of genetic resources, is already well documented (Safrin 2004, Halewood 
2014, and others), so we include only the briefest description here. Biotechnology 
breakthroughs in the 1980s, combined with expanded intellectual property 
protections, raised concerns about the different ability of developed and developing 
countries to benefit from the use of genetic resources. One response has been to 
promote international rules for access and benefit-sharing which promote national 
sovereign control over genetic resources.  
Despite the fact that the international community has, in recent decades, been able 
to agree upon a number of international conventions concerning intellectual property 
protections and access and benefit-sharing , legal certainty and predictability 
concerning availability and use genetic resources has not, in general, been 
increased. Indeed, in some ways, it continues to decrease. This is both reflected, and 
perpetuated, by the fact that shortly after most of these international conventions 
were adopted, international processes were launched to review and revise them (or 
develop new international laws), driven by dissatisfaction with their impact and/or by 
new technological developments that threaten to make them obsolete.
Recent breakthroughs in genome sequencing and high 
throughput phenotyping, combined with gene editing and 
gene synthesis technologies, are exacerbating concerns 
that commercial users can profit from the use of genomic 
sequence data, without having to share benefits under the 
existing framework of international access and benefit-
sharing agreements, but still have the possibility of enjoying 
intellectual property protections for those inventions.
The result is a new generation of what continue to be heated contested negotiations 
in multiple international fora about technology, equity, intellectual property and 
access and benefit-sharing.
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One knock-on effect of this international level dynamism, is that many countries’ 
national laws are also in a state of flux. This is partly due to the fact that it usually 
takes several years for national systems implementing international agreements 
to be put in place. But it is also a function of the fact that, because of lingering 
dissatisfaction and uncertainty in the overall balance of rights and obligations that 
have been struck to date across the international legal framework, many contracting 
parties are reluctant to invest resources in developing implementing measures. 
Alternatively, some countries have adopted new implementing measures ‘on paper’, 
but they are delaying making requisite investments to make them fully operational 
until the outcomes of ongoing international discussion and negotiations are clearer. Of 
course, many countries have made requisite investments to make their national laws 
and regulations functional, certain and predictable, but is sometimes hard ‘from the 
outside’ to distinguish between them. All of this, of course, contributes to a lack of 
clarity and predictability for researchers and other genetic resources users about the 
rules and conditions that apply to owning, controlling, accessing and using genetic 
resources and associated information in different countries.
While less politically contentious, internationally coordinated and nationally 
implemented systems to prevent the spread of diseases through the transfer of 
biological materials, can also have major impacts on researchers’ ability to access 
genetic resources.
In this decision-making tool, we will include consideration 
of risks associated with the operation of national systems 
pertaining to plants in particular, i.e., those which implement 
the International Plant Protection Convention.
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The structure and logic of this decision-making tool
Section 2 of this tool, immediately following this introduction, presents 4 successive 
stages in the life cycle of a typical large research and development project that 
involves accessing and pooling genetic resources and related information and 
technologies from multiple sources. For each of those stages, we list the risks to the 
project and to the subsequent take-up of the project’s results.  
In Section 3, we focus on the policy and legal issues that that are associated with 
accessing and using genetic resources and related information and technologies, that 
can contribute to the risks.
For each of these policy and legal issues we include:
1 the questions that research planners need to address to evaluate the 
extent of the particular risk, taking into consideration the state of laws 
and policies in the countries where partners are located, where research 
and development activities are carried out, and ultimately, where research 
products will be disseminated, including the manner in which these laws 
and policies can affect (positively or negatively) those risks.
 
2 tips for addressing those risks at the planning stage of the project.
Section 4 proposes overall strategies that project planners can adopt as part of their 
risk-mitigation efforts.
The EUCLEG project
The Horizon 2020-funded project “Breeding forage and grain legumes to increase 
the European Union’s (EU) and China’s protein self-sufficiency” (EUCLEG project) has 
involved 37 participants from more than 10 countries (both EU and non-EU). It has 
relied on the sharing and characterization of wide collections of genetic resources of 
the target crops (alfalfa, red clover, white clover, pea, faba bean and soybean) for 
identifying valuable trait variation to be introduced into current elite material used in 
breeding programs. 
One of the research packages built into the EUCLEC project from the very beginning, 
involved monitoring the impacts of genetic resources-related policies at institutional, 
national and international levels on project activities. This has facilitated more 
systematic, project-wide reflection on these issues than is often the case, where 
policy challenges are experienced as an incident of practical project administration. 
It is not the purpose of this decision-making tool to enter into details of challenges 
encountered during the EUCLEG project. Those are documented elsewhere (Bedmar 
et al. 2020). That said, the experience of the EUCLEG researchers has allowed 
the project to identify the main legal and policy-related issues that individual 
researchers, research organizations and research consortia face when acquiring, 
sharing and using germplasm, related information and technologies in the first place; 
and then generating and disseminating research results based on genetic resources 
and related information and technologies. It has also allowed the project to explore 
ways to anticipate and address policy and legal issues at early stages, in order to 
ensure compliance, minimize inefficiencies and avoid restrictions to the dissemination 
of research results, including in the form of new commercial products. 
This decision-making tool builds on the EUCLEG project experiences, aiming to 
provide guidance to researchers who embark in similar research projects and 




POTENTIAL RISKS OVER AN R&D 
PROJECT’S LIFECYCLE
Assembling the research inputs, including genetic resources
Risk: Project partners are unable to acquire genetic resources and other research inputs 
from provider organizations within or outside the research consortium.
Contributing factors: 
Potential providers’ feeling that the project will not generate sufficient benefits for 
them 
Access and benefit-sharing laws
Political sensitivities around the sharing of genetic resources
Intellectual property rights over the genetic resources, related information and 
technologies
Provider partners do not actually have the authority or legal right within 
their organization to share the 
research inputs
Phytosanitary regulations
Product development and commercialization
Risk: Potential users of the projects’ 
results face challenges to take up the research results and to use them for the 
development of commercial products.
Contributing factors: 
The conditions under which the research inputs were acquired limit commercial 
users’ ability to use them for producing marketable products 
Users cannot show ABS due diligence
Benefit-sharing obligations become too heavy a burden for commercial users
Disseminating the research results
Risk: Project partners are not willing or able to share or disseminate the 
project’s results.
Contributing factors: 
Restrictive conditions in the agreements under which the genetic resources and 
other research inputs were acquired 
Disagreements concerning control and dissemination of research results 
Data exchange within the project
Risk: Project partners do not share with one another the data and information they 
have generated.
Contributing factors: 
Lack of commitment with the project’s goals
Unclear rules about data ownership and data sharing
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ADDRESSING RISKS AT THE PLANNING 
STAGE OF AN R&D PROJECT
Dealing with issues related to the access to genetic resources 
and the sharing of benefits arising from their use
Introduction
If you embark on a research project with activities that 
depend on the access to and use of genetic resources coming 
from different countries and organizations, you will surely 
have to address questions around who has the right to control 
access to genetic resources, who can use them, and who can 
benefit from the results of the research.
Laws regulating the access to genetic resources and the 
sharing of the benefits arising from their use (ABS) are 
designed to address these issues. There are two types of 
ABS frameworks: under bilateral frameworks each transfer is 
negotiated bilaterally between the provider and the recipient; 
under a multilateral framework everyone agrees that every 
transfer will be subject to the same set of rules, which are 
negotiated in advance. The International Treaty on Plant 
Genetic Resources for Food and Agriculture (the Plant Treaty) 
establishes a multilateral system for the exchange of a set of 
plant genetic resources to be used for research, training and 
breeding in food and agriculture. 
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Despite efforts made by the international community and 
by countries to put ABS systems in place, many research 
organizations are based in countries where there is still much 
tension around the sharing of genetic resources, and mistrust 
and discomfort among researchers. In some countries, national 
ABS laws have established long and cumbersome access 
procedures that researchers often find difficult to navigate. 
For these and other reasons, it may happen that the provider 
organizations that you would like to engage in your project, 
feel reluctant to provide samples of the genetic resources 
they hold, or that they try to impose restrictive conditions 
that limit project partners’ ability to use the genetic 
resources for the purposes of the project, to disseminate the 
research results, or to employ them in the development and 
commercialization of products at the end of the R&D chain. 
In an increasing number of countries, as a result of the 
implementation of the Nagoya Protocol on the Access to 
Genetic Resources and the Sharing of the Benefits Arising from 
their Use, systems are being put in place for monitoring if 
users have obtained the permits required by the national laws 
and regulations of the provider countries. In the European 
Countries, the EU ABS Regulation 511/2014 on compliance 
measures for users sets up the overall monitoring framework 
in EU countries. According to this Regulation, project partners 
that are based in the EU need to demonstrate that they have 
acquired the genetic resources in accordance with applicable 
laws. Otherwise, they may not be able to obtain funding, 
disseminate the research results (including in scientific 
journals), obtain intellectual property rights over them, 
and exploit them through commercial products. In addition, 
not being able to demonstrate due diligence may put these 
partners’ reputation at risk, and may generate mistrust among 
their collaborators and donors.
9Are the provider organizations from which the project partners expect to  obtain the genetic 
resources, interested or motivated to provide access?
Risk 
Project partners cannot obtain the genetic resources 
necessary for the project (1/3)
Are the provider organizations from which the project partners expect to 
obtain the genetic resources interested or motivated to provide access?
If not, are there benefit-sharing options 
that may encourage the provider 
organizations to change their perception 
and become more inclined to provide 
the genetic resources?
If so, what kinds of benefit-sharing are 
the organizations interested in?
If not, can alternative providers of the 
same genetic resources be considered?
If not, can you revise the project’s 
plans so that it does not depend on 
those particular genetic resources?
Can the project afford them?
TIPS
ABS rules were developed largely in response to a sense 
(particularly among countries that are often historical 
‘providers’ of genetic resources) that more, and more 
creative benefit-sharing from R&D projects is necessary. So 
it makes sense to build serious consideration of 
benefit-sharing into your project plans. You can consider, 
among other measures, greater involvement of that 
organization in the project, participating in the 
identification of research priorities, getting funding for R&D 
activities that is part of the project, sharing ownership in, 
or getting priority access to, research results, capacity 
building and technology sharing, a share in royalties from 
downstream licensees of project outputs,  maybe even 
agreements for research collaboration beyond the project. 
One of the criteria for choosing research partners and 
potential providers of genetic resources and related 
information can be organizations’ reputation for providing 
access to germplasm, and their experience and agility in 
dealing with germplasm requests. If you don’t think the 
benefits you can offer through the project can overcome 
their demonstrated past reluctance, it is important to 
recognize that up front, and make other plans. 
For plant genetic resources available through the Plant 
Treaty’s multilateral system, access and benefit-sharing 
terms are already ‘pre-agreed’ by contracting parties in the 
form of a Standard Material Transfer Agreement (SMTA).  In 
theory, if materials you want are included in the 
multilateral system, then you should be able to get 
facilitated access to them under the SMTA. The challenge 
here is that it can be hard for the project partners to know 
for certain if a particular plant genetic resource for food 
and agriculture (PGRFA) is actually available through the 
multilateral system, or if it falls under some other national 
regulatory framework.   
Can the potential provider organizations 
obtain permission  to give access to the genetic 
resources?
Risk
Can the potential provider organizations obtain permission 
to give access to the genetic resources?
If not, is it because the applicable laws regulating 
the access to genetic resources and the sharing of 
benefits arising from their use (ABS) are unclear, 
or the access procedures long and cumbersome, or 
simply not operational because implementing 
systems are under-resourced?
If so, can the project afford to spend the 
time and resources necessary for obtaining 
the access permits?
If not, can you revise the project’s 
plans so that it does not depend on 
those particular genetic resources?
If not, can alternative providers of the 
same genetic resources be considered?
If not, is it because the organization originally 
acquired the genetic resources subject to 
conditions that restrict their transfer to 
further users? 
If so, can the project partners go to the 
original providers and obtain the genetic 
resources under more permissive conditions?
If not, can you revise the project’s plans 
so that it does not depend on those 
particular genetic resources?
If not, can alternative providers of the same 
genetic resources be considered?
TIPS
Here, the focus is on the national laws and not on the provider per se. The provider may be willing to provide 
the resource, but not be able to get permissions at all, or in a timely manner, from the competent national 
authorities. In order to understand the difficulties, become familiar with access and benefit-sharing rules in the 
potential providers’ countries (including those of planned partners). Your potential partners are a good place to 
start asking for feedback about the national laws. In addition, for information about national ABS laws 
implementing the Convention on Biological Diversity (CBD)/Nagoya Protocol, you can consult the ABS Clearing 
House, which provides information about national ABS regimes: https://absch.cbd.int/. You can also get in 
touch with national ABS authorities (also listed in the ABS Clearing House) and request guidance. As far as 
whether or not materials are available under the Plant Treaty’s multilateral system, you can ask the potential 
providers. Another potential source of information is the Plant Treaty National Focal Point, who is listed on the 
Plant treaty website at http://www.fao.org/plant-treaty/countries/national-focal-points/en/.
One of the criteria for choosing research partners and potential providers of genetic resources can be the clarity 
of their country’s national ABS regimes and whether the process for obtaining access permits seems friendly, for 
example by providing simplified procedures for the acquisition of genetic resources for research purposes.
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Project partners cannot obtain the genetic resources  
necessary for the project (2/3) 
Will provider organizations require  monetary 
benefit-sharing?
Risk
Will provider organizations require 
monetary benefit-sharing?
If so, can the project afford the required payments?
If not, can they be negotiated?
If not, can you revise the project’s plans 
so that it does not depend on those 
particular genetic resources?
If not, can you consider alternative 
providers?
If not, does the project want to voluntarily 
assume some form of monetary 
benefit-sharing?
TIPS
Learn about partners and providers’ policies and practices in relation to monetary benefit-sharing: What rates 
they apply for monetary benefit-sharing; when the obligation to make payments as monetary benefit-sharing is 
triggered (e.g. when using the genetic resources, when disseminating the research results; when 
commercializing research-based products); and what reporting conditions they require to monitor compliance 
with monetary benefit-sharing obligations.  
Monetary benefit-sharing obligations have not only financial implications, but they may also imply transaction 
costs derived from the need to track, trace and report how the genetic resources have been used, the extent to 
which they have contributed to commercial products, and the revenue portion that is allocated to 
benefit-sharing. Evaluate the financial and transaction costs at the planning stage, and their potential 
implications for the project partners and for the actors you want to see using the project’s research results. 
Put in place mechanisms to ensure that project partners pass onto commercial users the benefit-sharing 
obligations that will be triggered at the commercialization stage. One clear case is the monetary benefit-sharing 
obligation under the Standard Material Transfer Agreement of the International Treaty on Plant Genetic 
Resources for Food and Agriculture. This SMTA requires companies to pay a percentage of the monetary benefits 
obtained from the commercialization of new varieties that incorporate any level of the germplasm they 
received with the SMTA, whenever the new varieties are not available for further research and breeding. If 
project partners have obtained genetic resources through the SMTA and they pass research results which 
incorporate these genetic resources to commercial actors who will exploit them commercially, they have to 
make sure that they pass on the benefit-sharing obligations of the SMTA onto the commercial actors. 
Even if genetic resource providers do not require monetary benefit-sharing, the project partners could agree to 
assume payments on a voluntary basis, or to require commercial users to assume the payments. There may be 
strong reasons for doing this, for example to provide incentives for the provider organization to facilitate access 
to their genetic resources, to reinforce collaboration with the provider organization, to improve the reputation 
of the project and the project partners, and to facilitate progress towards the project’s objectives.
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Project partners cannot obtain the genetic resources  
necessary for the project (3/3)
Will provider organizations try to impose 
conditions that may limit project  partners’ 
ability to 1) share the data generated by the 
research with other project partners;  and 
2) disseminate the research results (data, 
methods, genomic tools, improved  lines or 
strains) in the ways envisaged by the project?
Risk 
Project partners cannot disseminate the research results 
derived from the use of the genetic resources
Will provider organizations try to impose conditions that may limit project 
partners’ ability to 1) share the data generated by the research with other project partners; 
and 2) disseminate the research results (data, methods, genomic tools, improved 
lines or strains) in the ways envisaged by the project?
TIPS
Evaluate the potential conditions that providers of 
genetic resources may try to impose. For example, if 
project partners are obliged to get approval from the 
providers before sharing the research results with other 
project partners or with potential users, the 
transaction costs will increase considerably at the 
dissemination phase. If the providers ban the sharing of 
the research results with certain users (for example 
companies who may exploit the project’s products 
commercially), the range of actors who can benefit 
from the project may be seriously restricted.
If so, can the conditions be negotiated?
If not, can you revise the project’s 
plans so that it does not depend on 
those particular genetic resources?
If not, can you consider alternative 
providers of genetic resources?
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Will provider organizations try to impose 
conditions that may limit the ability of your 
 target commercial users to exploit the research 
results?
Risk 
Target commercial users cannot exploit  
the research results
Will provider organizations try to impose conditions that may limit the ability of your 
target commercial users to exploit the research results?
TIPS
If so, can the conditions be negotiated 
at the time of assembling the genetic 
resources?
If not, can you get some assurance that 
there will be a constructive negotiation 
down the road, once the research results 
demonstrate market potential?
If not, can you revise the project’s 
plans so that it does not depend on 
those particular genetic resources?
If not, can you consider alternative 
providers of genetic resources?
Map and characterize the commercial actors that you 
want to see using your research results (e.g. breeding 
companies). Some may be already partners in the 
project. Understand the conditions that would make it 
difficult for them to convert the project’s research 
results into commercial products. For example, 
limitations to sell the products in relevant markets, 
restrictions to claim intellectual property rights over the 
products, or requirements to share a substantial 
proportion of royalties or other benefit-sharing conditions 
that they consider unduly onerous. 
If you can’t secure freedom to operate for your 
commercial target users at the time of assembling the 
portfolios of the genetic resources, you can try and come 
up with a strategy to facilitate the negotiation between 
the relevant providers or partners and the relevant 
commercial actors once it becomes clear that certain 
research results have a market potential.  
Try to define the outer limits of negotiable conditions 
with potential partners and providers, in order to 
minimize the risk of them introducing conditions that will 
in practice make getting project deliverables scaled up 
and out impossible. 
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Will project partners and further users of the 
research results be able to demonstrate that 
the genetic resources used in the project were 
obtained in accordance with applicable ABS 
laws?
Risk 
Project partners cannot demonstrate  
ABS due diligence
Will project partners and further users of the research results be able to demonstrate that the 
genetic resources used in the project were obtained in accordance with applicable ABS laws?
TIPS
Become familiar with the requirements of the ABS 
checkpoints in the countries where you and your target 
users will operate. Checkpoints are required by the 
Nagoya Protocol on ABS for all its member states, and 
have the objective to monitor if users comply with the 
ABS requirements imposed by the provider countries. 
Checkpoints may include ministries of research, funding 
agencies, intellectual property offices and public 
agencies for the registration of new commercial 
products. Proof of due diligence required by the 
checkpoints may include international certificates of 
compliance, access permits and and material transfer 
agreements. 
Set up a documentation system that helps you keep 
records of project partners’ acquisitions, and of the 
conditions that apply to each genetic resource used in 
the project. 
Be prepared to share the necessary documentation with 
users of research results who may need to show due 
diligence when conducting further research or developing 
and commercializing products. Checkpoints may also 
want to see proof that you received materials under the 
SMTA. While germplasm transfers under the multilateral 
system is not within their jurisdiction, it may be that the 
only way they can know this is the case is to see proof 
you obtained it under an SMTA.   
If so, what proof of compliance will they 
have to present?
Do project partners have the requisite 
proof, or can they acquire it?
If not, can the project afford the consequences 
of not demostrating compliance?
If not, can you revise the project's plans 
so that it does not rely on genetic 
resources for which project partners 
cannot show due diligence?
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Acquiring research inputs that are subject to intellectual  
property rights
Introduction
The research project may need to use genetic resources, 
related information, technologies, methods and other 
inputs that may be subject to intellectual property rights. 
In fact, with the raise of intellectual property protection 
in biotechnologies in general, and in technologies dealing 
with plant, animal an microorganisms used in agriculture in 
particular, it is likely that many research projects will be 
interested in using proprietary technologies in their activities. 
Genetically modified plants and animals, breeding methods, 
traits, genomic tools and other research resources can be 
subject to patents. Obtaining the licenses for using them in 
the project can be time consuming, and expensive. If you are 
planning to use cutting-edge biotechnologies, most probably 
you will have to deal with inventions that are subject to 
multiple patents, or acquire complementary technologies, 
each of them subject to its own patent. This increases the 
challenges involved in obtaining the necessary licenses.
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Plant varieties subject to plant breeders’ rights (PBR, or 
plant variety protection rights - PVP) that have been granted 
by countries who operate under the UPOV Convention can 
be used for further breeding by crossing and selection, 
and the resulting varieties can be commercialized without 
any obligation to seek the permission from the PBR holder. 
However, in practice, PBR owners may feel reluctant to 
provide access to their protected varieties to researchers 
who are based in countries where the varieties are not being 
commercialized if they suspect that the recipient organizations 
may subsequently use the varieties not only for further 
breeding, but also for multiplication and commercialization, 
without obtaining the necessary licenses. 
Fears can arise also at the time of disseminating the research 
results, and the commercial products derived from the 
project: project partners and commercial users may not want 
to release their proprietary technologies (including plant 
varieties and animal breeds) in countries where they feel that 
their property rights won’t be enforced, so others can simply 
access the materials on the open market and use them to 
enter into competition with the owner.
Does the project need to use genetic resources 
and related technologies  that are subject to 
intellectual property rights?
Risk 
Project partners cannot obtain genetic resources and related 
technologies necessary for the project
Does the project need to use genetic resources and related technologies 
that are subject to intellectual property rights?
If so, are the holders of the protected technologies willing to provide them to the project?
If yes, can the project afford the costs 
(financial and transaction costs)?
If not, is there a way to decrease the costs 
(e.g. engaging IPR owners as project 
partners; using alternative, substitute 
technologies that can be organized under 
more favorable terms)?
If not, is it because the intellectual property 
holder is afraid of misappropriation by some 
of the project partners?
If so, is this fear well founded?
If not, can the project address possible 
misperceptions?
If yes, perhaps there is nothing the 
project can do. Can the project find 
another partner or provider?
If not, is it because of the intellectual property 
holder’s own business strategy?
TIPS
Identify the research inputs that are subject to intellectual property rights in the countries where the project 
will operate and seek legal advice on the time and resources that you will need to invest in order to obtain 
the necessary licenses. 
Evaluate the project’s chances of acquiring patented technologies in a timely manner, taking into 
consideration the fees to be paid, the transaction costs, the research consortium’s ability to negotiate the 
licenses, and the benefits the project can realistically generate for the patent owner in return (in addition to 
the fees; e.g. reputation, access to cutting-edge technology and information, possibility of long-term 
collaboration with other research organizations). 
Investigate the intellectual property right culture within the partners’ organizations, and study the legal 
framework and enforcement mechanisms in the countries where research partners will be working with the 
protected materials. Assess whether the fear of misappropriation is founded, and explore ways to guarantee 
and reassure the providers of proprietary materials and technologies. There may be cases in which getting 
meaningful protection in the country concerned will be impossible. If intellectual property protection is 
crucial for key project partners, you may want to decide to work somewhere else.  
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Will providers of genetic resources and related 
technologies that are subject to Intellectual 
Property Rights try to impose conditions 
that may limit project partners’ ability to 
disseminate  the research results in the ways 
envisaged by the project, and their take up by 
further users,  including commercial actors?
Risk 
Project partners cannot disseminate the research results  
derived from the proprietary genetic resources  
and related technologies
Will providers of genetic resources and related technologies that are subject to Intellectual 
Property Rights try to impose conditions that may limit project partners’ ability to disseminate 
the research results in the ways envisaged by the project, and their take up by further users, 
including commercial actors?
If so, can the conditions be negotiated?
If not, can you revise the project’s plans so that it 
does not depend on those proprietary technologies?
If not, can you consider alternative or substitute 
technologies?
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Are project partners and target commercial 
users reluctant to disseminate results  and 
products over which they intend to claim 
intellectual property rights?
Risk 
Project partners and target commercial users do not want to 
disseminate research results and derived commercial products
Are project partners and target commercial users reluctant to disseminate results 
and products over which they intend to claim intellectual property rights?
TIPS
If so, is it because they are afraid that their 
intellectual property rights won’t be respected and 
enforced in some of the project’s target markets?
If so, is this fear well-founded? 
If not, can the project address possible 
misperceptions?
Study the legal framework and enforcement 
mechanisms for intellectual property rights in the 
countries where you want to see the project results 
converted into commercial products, possibly subject to 
property rights. Assess the risk that the new products be 
misappropriated, and the extent to which 
misappropriation can represent a big disincentive for 
project partners and target commercial users.  




Ensuring legal rights for sharing germplasm
Introduction
Researchers involved in the project may assume that they 
have the legal authority to commit their organizations to 
share genetic resources with the other project partners, and 
later in the project, when the time arrives to send the genetic 
resources, they may find out that they don’t have such rights. 
In order to avoid this situation, you and your research partners 
must verify your own capacities and rights to make legally 
binding agreements on behalf of your organization to share 
germplasm. This verification should take place at the planning 
stage, and certainly before committing to contribute the 
selected genetic resources to the project.
Do the individuals you are engaged with in 
planning the project have the authority to 
agree,  on behalf of their organizations, to share 
genetic resources for the project purposes?
Risk 
Project partners cannot provide access to genetic resources 
they hold and that are necessary for the project
Do the individuals you are engaged with in planning the project have the authority to agree, 
on behalf of their organizations, to share genetic resources for the project purposes?
TIPS
Confirm that individual researchers from different 
organizations involved in your project have the 
authority to make legally binding undertakings to 
provide germplasm or related information on behalf of 
their organization. If they do not, get such assurances 
from people in their organization that do have such 
authority; before project planning and partnership 
formation processes are complete.    
If not, is there an institutional policy that 
prevents them from obtaining authorization?
If not, can alternative providers of 
the same genetic resources be 
considered?
If not, can you revise the project’s 
plans so that it does not depend on 
those particular genetic resources?
If not, can they obtain the authorization 
from the relevant managers? 
21
22
Dealing with phytosanitary regulations
Introduction
Phytosanitary regulations restrict or prohibit the importation 
of certain plant species, or products of these plants, so as to 
prevent the introduction or spread of plant pests or pathogens 
that these plants may be carrying. These regulations can 
have a big effect on the actual movement of samples across 
countries and regions. 
Certain plants and plant products entering the European 
Union must have an import permit issued by EPPO and a 
phytosanitary certificate guaranteeing that they are properly 
inspected; free from quarantine and any regulated pests, and 
in line with the plant health requirements of the EU as per 
conditions given in the import permit. The exporting country's 
national plant protection authorities issue the phytosanitary 
certificates. Once in the EU, a plant passport may replace the 
phytosanitary certificate for imported plants, plant products 
and other objects, for movement within the EU region.
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Plant protection agencies in exporting countries may have 
limited capacities to issue phytosanitary certificates with 
sufficient declarations demanded by the importing country, 
and/or plant protection agencies in importing countries 
may not consider the phytosanitary certificates issued by 
certain countries reliable or sufficient. These limitations can 
delay or block the movement of genetic resources among 
providers and recipients in your project. EPPO authorities 
could hold the material for further inspection and testing. 
This could result in a substantial delay in accessing the 
material, and potential loss of the material found to be 
contaminated with pests. Overcoming these potential 
challenges requires advance planning and advance action (3 
to 12 months ahead depending on the species; vegetatively 
propagated germplasm requires long time than the seed 
crops). In addition, you must take into consideration the 
costs associated with the phytosanitary controls, as well as 
possible additional tests required in certain countries. For 
example, some countries may require tests for checking 
presence of genetically modified organisms (GMOs). 
Are the samples of genetic resources that you 
want to assemble for the project subject to 
phytosanitary requirements?
In addition to a phytosanitary certificate, what 
other regulator documents may be necessary? 
(e.g., customs clearence; declaration of GMO 
status)
How long does the import process normally 
take? How much do the procedures cost?
Will GMO testing be required?
Risk 
Project partners cannot obtain genetic resources necessary for the project
TIPS
Are the samples of genetic resources 
that you want to assemble for the 
project subject to phytosanitary 
requirements?
If so, do project partners and other potential 
providers have capacities to issue bonfide 
phytosanitary certificates?
If not, can you revise the project’s 
plans so that it does not depend on 
those particular genetic resources?
If not, can alternative providers of the 
same genetic resources be considered?
Can provider organizations and project 
partners provide all the necessary 
documentation?
If not, what alternative options 
can be considered?
Can the project afford the expected costs 
and delays?
If not, can you revise project plans in order 
to avoid import of genetic resources in the 
most problematic countries?
How long does the import process normally 
take? How much do the procedures cost?
Will GMO testing be required?
Become familiar with phytosanitary requirements in the countries where you need to send or receive the 
material, and anticipate possible problems and delays at customs. Identify the quarantine pests and the 
regulated non-quarantine pests that may affect the import of samples your project plans to use. Bear in mind 
that phytosanitary requests change in response to the emergence of new pests and diseases, and new 
methods for controlling them. And that it sometime occurs that out of an abundance of caution, some 
countries require proof of absence of diseases that are not known to affect the genera or species in question.
Keeping up to date on international, regional and national requirements in relation to the species you work on 
will help you avoid surprises. You can check the EU websites for these purposes: 
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02016R2031-20191214; 
https://eur-lex.europa.eu/eli/dir/1992/103/oj.
Be prepared for GMO controls, particularly if the project works with plant, animal or microorganism species 
for which GMO varieties, breeds and strains have been approved and are already commercialized in the 
provider organization’s country, and banned in the recipient organization’s country. The rules of the exporting 
and the importing country may require that the provider organization demonstrates that the presence of GMO 
plants in the sample is below a certain threshold. This requires rigorous, certified testing of the whole sample.
In addition to a phytosanitary certificate, 
what other regulator documents may be 
necessary? (e.g., customs clearance; 
declaration of GMO status)
If so, can the provider organization carry 
out the testing?




Defining common strategies for  
results’ dissemination and exploitation
Introduction
Your project results may include information (e.g. phenotypic 
and genotypic data), genomic tools (e.g. expressed sequence 
tags-ESTs, molecular markers, genetic maps), bioinformatic 
tools (e.g. software, algorithms), research and breeding 
methods, and improved varieties, breeds or strains.
The success of your research project will be determined by 
the extent to which the project partners and your target users 
take up these research results and use them in their own work, 
either directly, in the form you release them, or for further 
research, and for the development of new products such as 
new plant varieties and animal breeds. 
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Partners’ preferences in relation to the dissemination of the 
results can affect how project partners share information they 
have generated with one another, and how they disseminate 
the research results. Some partners may be bound by 
institutional policies that require them to treat the results of 
their research as public goods, unless particular circumstances 
recommend putting restrictions on their availability. Other 
project partners may have the freedom, and the preference, 
to treat the project’s results as proprietary technologies and 
control their use through license agreements. Some project 
partners may prefer to share the research results with any 
interested user, while others may wish to provide exclusive 
rights over the research results to selected users. The donor 
or funding agency may impose its own conditions on product 
dissemination and exploitation.
Unless the project partnership agrees on a common approach 
and all project partners commit to it at the planning stage, 
conflicts might arise, and the dissemination of the project’s 
results may be compromised.
Do project partners agree with dissemination 
principles that best support  the project’s 
mission and objectives?
Risk 
Project partners do not share or disseminate research results 
as envisaged by the project
Do project partners agree with dissemination principles that best support 
the project’s mission and objectives?
TIPS
Identify divergences in the consortium members’ views on how the products should be 
disseminated, and assess the different options, from open access to exclusive and restrictive 
licenses. Do this assessment bearing in mind the project’s mission and objectives, the funding 
agencies’ requirements and the partner organizations’ policies and preferences.
Consider possible exceptions, embargos and flexibilities that the project partners can subject 
themselves to in order to accommodate their preferences and needs within the overall 
dissemination principles. For example:
Negotiate and agree on a common dissemination approach at the project’s planning stage, and 
spell it out in the partnership agreement. This will provide certainty to the project partners 
on a crucial aspect, and will help to avoid frustrations and negotiations at a later stage.
Willingness of organizations to align to a pre-determined dissemination approach (for 
example, open and free access to research results) may be one of the criteria for selecting 
the project partners. 
If not, can you include flexibilities and exceptions that will accommodate partners’ concerns and preferences 
without compromising the project’s mission and objectives?
The research consortium can agree to provide access to research data in an open and 
free manner, but the timeframe may be subject to certain flexibility. For example, 
exclusive rights over the data can be recognized for data generators over a limited 
number of years, or until the data are published in a scientific publication.
The research consortium can agree to provide access to the research results through 
exclusive or semi-exclusive licenses (provided that this is allowed by the donor and in 
line with the project’s objectives), but some exceptions to the exclusivity approach can 
be recognized. For example, project partners can be permitted to reserve themselves 
the right to make the results available to particular types of users (e.g. public research 
organizations) and for particular uses (e.g. non-commercial research for food and 








As soon as possible, and ideally before the project starts, begin negotiating the 
agreements about who will contribute what to the project, and under what 
conditions. Additionally in the early planning stage, discuss and agree on the 
principles that will govern the dissemination of the project results, and possible 
exceptions to the general dissemination strategy.
Starting early will give you time to negotiate with partners and potential 
providers, address requirements derived from national ABS laws, and explore 
options to address partners and providers’ possible reluctance or discomfort 
when sharing genetic resources and related information. This will also enable 
you to avoid situations in which a project partner or a provider unexpectedly 
rejects a request to provide germplasm it has originally committed, and which 
is necessary for the project’s activities, as well as situations in which project 
partners deny access to data they have generated throughout the project to 
other project partners, or try to impose restrictions on the dissemination of 
research results based on their own institutional policies and practices. 
Define your red lines
Anticipate situations you cannot accept. For example: the procedures for 
obtaining genetic resources takes longer than X months; the conditions imposed 
by the provider organization are too restrictive and will limit the project’s 
activities and objectives; the provider organization does not give permits in 
written form, or does not provide legal certainty otherwise.
OVERALL STRATEGIES FOR 
MINIMIZING RISKS
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Consider standardization of terms and conditions for the 
acquisition of genetic resources
At the planning stage, project partners can agree on the text of a common 
material transfer agreement (MTA) that will be used for all the transfers of 
germplasm within the project and which spells out the conditions that are 
acceptable for all project partners, from permitted uses to benefit-sharing 
arrangements.
Be conscious of partner’s different preferences, and understand that some 
partners may need to include different or additional conditions for sharing 
particular samples. These conditions may have been imposed by the original 
provider of those genetic resources, they may come from national ABS rules, or 
they may be required by the provider partner’s policies. The consortium must 
find the balance between setting common standards and respecting individual 
needs. For example, some partners may feel reluctant to share improved lines 
they have developed unless the material transfer agreement makes it clear that 
the samples cannot be used for purposes beyond the project, and particularly 
for seed multiplication and distribution. 
If you are dealing with plant genetic resources for food and agriculture, you 
will have to use the  Standard Material Transfer Agreement of the International 
Treaty on Plant Genetic Resources for Food and Agriculture for all transfers of 
plant germplasm that are included in the Plant Treaty’s multilateral system of 
access and benefit-sharing (MLS) (you can learn about collections/accessions 
that are  included in the multilateral system at http://www.fao.org/plant-
treaty/areas-of-work/the-multilateral-system/collections/en/; Genesys https://
www.genesys-pgr.org/  Eurisco https://eurisco.ipk-gatersleben.de/). If the 
PGRFA used in the project are not already included in the multilateral system 
you can nonetheless considering voluntarily using the SMTA for such transfers in 
the project if partners agree, and providers in each case have the legal right to 
do so.
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Assess the possibility of obtaining permits at two stages
Providers of genetic resources, information and technologies may be willing 
to provide access to their inputs under simple terms, and in a quick manner, if 
these are going to be used only for research purposes. In this case, providers 
usually impose the condition that if the resources, knowledge or technology 
is subsequently used for the development of commercial products, the user 
will have to obtain a new agreement with new terms and conditions, often 
pertaining to benefit-sharing arrangements. This two-step approach (i.e. 
first agreement for research purposes, and second agreement for product 
development) may be appropriate for your research project, since it minimizes 
transactions costs when acquiring genetic resources, information and 
technology, the value of which (for the development of commercial products) is 
still unknown. Once research results demonstrate where the market potential 
is, project partners or commercial users can go back to the original providers 
and negotiate a new agreement for the commercial exploitation of the selected 
genetic resources, information, technology, etc.
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Consider open access for disseminating the project results, 
and particularly data
Ample access, sharing and use of information (including phenotypic and 
genotypic characterization data) are considered the fuel for the furtherance 
of plant and animal research and breeding. Some of the biggest information 
platforms and databases, research consortia and research organizations have 
embraced the principle of providing free and open access to the data they 
generate and host. If your research consortium is publicly funded, you may need 
or want to apply this same approach to most of the data you will generate. In 
fact, some large funding programmes and agencies such as Horizon2020 require 
projects to implement open access. 
Open access does not necessarily mean absence of terms and conditions. If data 
are made available on existing databases, data access and use conditions of 
such databases will apply. Project partners will need to be aware of this from 
the beginning of the project, since this will influence the conditions they can or 
cannot accept from providers of research inputs. 
If the project sets up its own database, you may consider that certain conditions 
are met by data users in order to:
• protect the public nature of the data (for example intellectual property 
rights over the data or over data and products derived from the original data 
could be restricted); 
• recognize the source (for example attribution could be required); and
• increase legal certainty around data usage. National laws, institutional rules 
and obligations acquired through contracts (e.g. access agreements obtained 
with original providers of the genetic resources and related information) may 
also require partners in the research consortium to include certain terms and 
conditions for the use of data.
You need to be aware, as noted in the introduction, that there is currently 
disagreement in a number of international fora concerning the governance of 
genomic sequence information, particularly if and how monetary benefit derived 
from the commercial use of such information should be shared. As a result, this 
is a sensitive issue and should be explicitly discussed and agreements reached 
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